La maladie de Parkinson en France (serveur d'exploration) - Analysis (UK)

Index « Auteurs » - entrée « D. J. Brooks »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
D. Hot < D. J. Brooks < D. J. Burn  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 9.
Ident.Authors (with country if any)Title
000449 (2007) C. F. Lippa [États-Unis] ; J. E. Duda [États-Unis] ; M. Grossman [États-Unis] ; H. I. Hurtig [États-Unis] ; D. Aarsland [Norvège] ; B. F. Boeve [États-Unis] ; D. J. Brooks [Royaume-Uni] ; D. W. Dickson [États-Unis] ; B. Dubois [France] ; M. Emre [Turquie] ; S. Fahn [États-Unis] ; J. M. Farmer [États-Unis] ; D. Galasko [États-Unis] ; J. E. Galvin [États-Unis] ; C. G. Goetz [États-Unis] ; J. H. Growdon [États-Unis] ; K. A. Gwinn-Hardy [États-Unis] ; J. Hardy [États-Unis] ; P. Heutink [Pays-Bas] ; T. Iwatsubo [Japon] ; K. Kosaka [Japon] ; V. M.-Y. Lee [États-Unis] ; J. B. Leverenz ; E. Masliah [États-Unis] ; I. G. Mckeith [Royaume-Uni] ; R. L. Nussbaum ; C. W. Olanow ; B. M. Ravina ; A. B. Singleton ; C. M. Tanner ; J. Q. Trojanowski ; Z. K. Wszolek [États-Unis]DLB and PDD boundary issues : Diagnosis, treatment, molecular pathology, and biomarkers
000475 (2006) P. Remy [France] ; D. J. Brooks [Royaume-Uni]La dépression dans la maladie de Parkinson : perte de l'innervation dopaminergique et noradrénergique du système limbique
000504 (2005) Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne]Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary
000567 (2002) E. R. Brunt [Pays-Bas] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; J.-L. Montastruc [France] ; F. Stocchi [Italie]A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa
000608 (2000) O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
000642 (1998) A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie]The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
000643 (1998) A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study
000644 (1998) O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study
000649 (1998) D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni]A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease

List of associated KwdEn.i

Nombre de
documents
Descripteur
7Parkinson disease
7Treatment
6Antiparkinson agent
6Human
5Agonist
5Chemotherapy
5D2 Dopamine receptor
5Ropinirole
4Double blind study
3Comparative study
3Early
2Levodopa
2Nervous system diseases
1Aged
1Aminoacid
1Anatomic pathology
1Antiparkinson Agents (adverse effects)
1Antiparkinson Agents (therapeutic use)
1Benserazide
1Bromocriptine
1Clinical trial
1Critical study
1Decarboxylase
1Depression
1Diagnosis
1Disease-Free Survival
1Dopa
1Dopamine agonist
1Dopaminergic pathway
1Double-Blind Method
1Drug Therapy, Combination
1Drug combination
1Dyskinesia
1Dyskinesia, Drug-Induced (epidemiology)
1Dyskinesia, Drug-Induced (etiology)
1Dyskinesia, Drug-Induced (prevention & control)
1Enzyme inhibitor
1Female
1Fluctuations
1Follow up study
1Humans
1Incidence
1Indoles (adverse effects)
1Indoles (therapeutic use)
1Innervation
1Levodopa (adverse effects)
1Levodopa (therapeutic use)
1Limbic system
1Male
1Medicine
1Middle Aged
1Multicenter study
1Parkinson Disease (drug therapy)
1Prevention
1Prospective Studies
1Randomization
1Rasagiline
1Risk Factors
1Toxicity
1Treatment efficiency

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "D. J. Brooks" 
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "D. J. Brooks" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    D. J. Brooks
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024